Eko Health vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
Eko Health has sold 700,000+ digital stethoscopes with FDA-cleared AI for murmur, AFib, and low ejection fraction detection; AMA granted a Category III CPT code for its Sensora AI platform in 2025.
About
Eko Health is a medical technology company that has reimagined the stethoscope by integrating digital amplification, ECG capture, and artificial intelligence into a clinical-grade device for heart and lung auscultation. Its flagship product, the CORE 500™ digital stethoscope, features 40x sound amplification, active noise cancellation, a 3-lead ECG, a full-color display, and FDA-cleared AI algorithms for detecting heart murmurs, atrial fibrillation (AFib), and low left ventricular ejection fraction (LVEF) — a key indicator of developing heart failure. Eko has sold more than 700,000 stethoscopes worldwide, establishing broad clinical adoption ahead of any direct competitor.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.